Show simple item record

dc.contributor.advisorHarrison, Roger
dc.contributor.authorMcKernan, Patrick
dc.date.accessioned2018-11-01T20:40:38Z
dc.date.available2018-11-01T20:40:38Z
dc.date.issued2018-12-14
dc.identifier.urihttps://hdl.handle.net/11244/301994
dc.description.abstractThe unifying element tying together the therapeutics presented in this thesis is annexin A5. The protein, annexin 5 (ANXA5), is a membrane management protein that specifically binds to apoptotic cells. The natural ligand of ANXA5 displayed by apoptotic cells is phosphatidylserine. The aminophospholipid phosphatidylserine (Ptd-L-Ser) is a universal marker of mammalian cell stress. The expression of Ptd-L-Ser is triggered by a diverse range of cellular pathologies, most notably cellular trauma, oncogenesis, or infection. Annexin plays several critical roles in the pathogenicity of these disease states. Our previous work has demonstrated that ANXA5 derived therapeutics can be targeted to Ptd-L-Ser expression. In this thesis I build on this work, targeting several novel bioconjugates to Ptd-L-Ser expression.en_US
dc.languageen_USen_US
dc.subjectCanceren_US
dc.subjectMalariaen_US
dc.subjectBacterial Infectionen_US
dc.subjectBioconjugatesen_US
dc.titleTherapeutic Applications of Bioconjugates in Human Diseaseen_US
dc.contributor.committeeMemberMao, Chuanbin
dc.contributor.committeeMemberSikavitsas, Vassilios
dc.contributor.committeeMemberO'Rear, Edgar
dc.contributor.committeeMemberNollert, Matthias
dc.date.manuscript2018-11-01
dc.thesis.degreePh.D.en_US
ou.groupCollege of Engineering::Department of Bioengineeringen_US
shareok.nativefileaccessrestricteden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record